Display options
Cite
Kawasaki K, Hamamoto Y, Adachi M, et al. Early tumor cavitation with regorafenib in metastatic colorectal cancer: A case report. Oncol Lett. 2015;11(1):231-233doi: 10.3892/ol.2015.3905.
Kawasaki, K., Hamamoto, Y., Adachi, M., Kanai, T., & Takaishi, H. (2016). Early tumor cavitation with regorafenib in metastatic colorectal cancer: A case report. Oncology letters, 11(1), 231-233. https://doi.org/10.3892/ol.2015.3905
Kawasaki, Kenta, et al. "Early tumor cavitation with regorafenib in metastatic colorectal cancer: A case report." Oncology letters vol. 11,1 (2016): 231-233. doi: https://doi.org/10.3892/ol.2015.3905
Kawasaki K, Hamamoto Y, Adachi M, Kanai T, Takaishi H. Early tumor cavitation with regorafenib in metastatic colorectal cancer: A case report. Oncol Lett. 2016 Jan;11(1):231-233. doi: 10.3892/ol.2015.3905. Epub 2015 Nov 10. PMID: 26870193; PMCID: PMC4727027.
Copy Download .nbib Format: NLM
Share it on

Oncol Lett. 2016 Jan;11(1):231-233. doi: 10.3892/ol.2015.3905. Epub 2015 Nov 10.

Early tumor cavitation with regorafenib in metastatic colorectal cancer: A case report.

Oncology letters

Kenta Kawasaki, Yasuo Hamamoto, Masayuki Adachi, Takanori Kanai, Hiromasa Takaishi

Affiliations

  1. Division of Gastroenterology and Hepatology, Department of Internal Medicine, Keio University School of Medicine, Shinjuku-Ku, Tokyo 160-8587, Japan.
  2. Keio Cancer Center, Keio University School of Medicine, Shinjuku-Ku, Tokyo 160-8587, Japan.

PMID: 26870193 PMCID: PMC4727027 DOI: 10.3892/ol.2015.3905

Abstract

Tumoral cavity formation is a characteristic phenomenon reported in anti-angiogenic therapy in lung lesions. A 57-year-old male with multiple pulmonary metastases from colorectal cancer treated with an oral tyrosine kinase inhibitor, regorafenib, exhibited a characteristic cavity formation after the first two cycles. The decrease in the size of tumors was calculated as 38%, and there were associated decreases in the serum concentrations of the tumor markers carcinoembryonic antigen and CA19-9. After eight cycles of treatment, the cavity gradually disappeared through filling-in. This unique morphological response is not only reported in lung cancer but also in liver metastasis in colorectal cancer. However, the association between morphological changes including cavity formation and clinical benefit remains controversial. Pulmonary hemorrhage and pneumothorax are well-known consequences of cavitation, as reported with the other anti-angiogenic inhibitors. Early tumor cavitation in lung metastasis may demonstrate the predictive potential of regorafenib in colorectal cancer, although it is necessary to be mindful of toxicity.

Keywords: cavity formation; colorectal cancer; lung metastasis; regorafenib

References

  1. Lancet. 2013 Jan 26;381(9863):303-12 - PubMed
  2. Clin Sarcoma Res. 2014 Oct 01;4:14 - PubMed
  3. Cancer Imaging. 2012 Jun 29;12 :225-35 - PubMed
  4. J Thorac Oncol. 2008 Apr;3(4):351-7 - PubMed
  5. Lancet. 2013 May 4;381(9877):1537 - PubMed
  6. J Clin Oncol. 2009 Jan 20;27(3):404-10 - PubMed
  7. Lung Cancer. 2007 Jun;56(3):465-8 - PubMed
  8. JAMA. 2009 Dec 2;302(21):2338-44 - PubMed

Publication Types